Add a bookmark to get started

Abstract building
3 October 20213 minute read

Ardith Bronson, Isabel De Obaldia and Rebecca Jones McKnight named to The American Lawyer’s list of 2021 South Trailblazers

DLA Piper is pleased to announce that Ardith Bronson, Irma Isabel De Obaldia and Rebecca Jones McKnight have been named to The American Lawyer’s inaugural list of South Trailblazers. The list recognizes professionals in the South “who have moved the needle in the legal industry.”

Based in the firm’s Miami office, Bronson primarily focuses her practice on complex commercial litigation in the healthcare industry and represents clients in wide-ranging litigations involving unfair and deceptive trade practices statutes, ERISA, Medicare, False Claims Act, Anti-Kickback Statute, RICO and other claims impacting the managed-care industry. She is also a member of DLA Piper’s North American Pro Bono Committee who has devoted many of her pro bono efforts to death penalty advocacy and representing indigent criminal defendants.

De Obaldia is based in Northern Virginia and focuses on strategic intellectual property counseling, licensing, privacy and information security, data rights, technology procurement and transfers, distribution and licensing of intellectual property-related agreements, software licensing, development, distribution and procurement, manufacturing agreements and OEM relationships, Internet law, e-commerce, hosting and cloud services, trade secrets and non-disclosure, M&A technology counseling, and general business counseling for technology companies.

McKnight advises clients who develop, make and distribute FDA-regulated products and who play a part in the investigation and delivery of healthcare products and services. She is based in Austin and provides strategic regulatory counseling to help clients commercialize products and services and establish and maintain compliant operations. She has extensive experience developing policies and procedures for FDA and healthcare compliance; conducting proactive reviews, risk assessments and internal compliance investigations; and correcting and remediating non-compliance.

Print